SCHEMBL4935879

SCHEMBL4935879

Cc1ccc(-c2ccc(N(CC(=O)O)S(C)(=O)=O)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.65
NFE2L2 Q16236 3/20 0.65
SMN1; SMN2 Q16637 2/20 0.60
MMP2 P08253 2/20 0.55
MMP9 P14780 2/20 0.55
PPARG P37231 1/20 0.52
ALDH1A1 P00352 2/20 0.51
KMT2A Q03164 3/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.47
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PTGES O14684 1/20 0.46
ALOX5 P09917 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4934333 0.89 SMN1; SMN2 (0.70) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL4933383 0.84 SMN1; SMN2 (0.57) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL4927214 0.83 KEAP1 (0.68) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL4930713 0.82 SMN1; SMN2 (0.55) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL697566 0.81 SMN1; SMN2 (0.73) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL4934273 0.81 SMN1; SMN2 (0.64) KEAP1NFE2L2SMN1; SMN2ALDH1A1NPC1
SCHEMBL24279764 0.80 MMP2 (0.57) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL1409649 0.80 SMN1; SMN2 (0.63) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL18263620 0.80 SMN1; SMN2 (0.63) KEAP1NFE2L2SMN1; SMN2MMP2MMP9
SCHEMBL2558736 0.79 SMN1; SMN2 (0.61) KEAP1NFE2L2SMN1; SMN2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227858-A1 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED 2008-09-18 US disclosed
US-20080227858-A1 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED 2008-09-18 US disclosed
US-20080227858-A1 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED 2008-09-18 US disclosed
US-7375248-B2 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED (GB) 2008-05-20 US disclosed
US-7375248-B2 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED (GB) 2008-05-20 US disclosed
US-7375248-B2 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED (GB) 2008-05-20 US disclosed
US-20060142385-A1 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED (GB) 2006-06-29 US disclosed
WO-2004113279-A1 INHIBITORS OF MATRIX METALLOPROTEINASE GLAXO GROUP LIMITED (GB) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142385-A1 Inhibitors of matrix metalloproteinase MMP9, MMP13, MMP26 KEAP1 3242/4885NFE2L2 2513/4885SMN1; SMN2 3337/4885
US-20080227858-A1 Inhibitors of matrix metalloproteinase MMP9, MMP13, MMP2 KEAP1 3156/4885NFE2L2 2605/4885SMN1; SMN2 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.